January 2016 - Biowebspin | Biowebspin
Logo Biowebspin

Archives January 2016 - Biowebspin

Developing a Framework to Manage a Pharmaceutical Innovation Ecosystem: Collaboration Archetypes, Open Innovation Tools, and Strategies

Developing a Framework to Manage a Pharmaceutical Innovation Ecosystem: Collaboration Archetypes, Open Innovation Tools, and Strategies

  Biowebspin, January 28th, 2016 Developing a Framework to Manage a Pharmaceutical Innovation Ecosystem: Collaboration Archetypes, Open Innovation Tools, and Strategies by David Tamoschus, Christoph Hienerth, Monika Lessl at the 2nd World Open Innovation Conference Based on an in-depth case study of the ecosystem of one of the world ́s largest healthcare companies including internal and external d... »

Open Access Could Transform Drug Discovery: A Case Study of JQ1

Open Access Could Transform Drug Discovery: A Case Study of JQ1

  Biowebspin, January 25th, 2016 Open Access Could Transform Drug Discovery: A Case Study of JQ1 by Arshad Z, Brindley D, Smith J, Roberts M, Lee WH, Davies B, Bure K, Hollander GA, Dopson S, Bountra, in Expert Opinion on Drug Discovery, 2016 Introduction: The cost to develop a new drug from target discovery to market is a staggering $1.8 billion, largely due to the very high attrition rate of dru... »

Cross-border R&D alliance networks: an empirical study of the umbilical cord blood banking industry in emerging markets

Cross-border R&D alliance networks: an empirical study of the umbilical cord blood banking industry in emerging markets

  Biowebspin, January 22th, 2016 Cross-border R&D alliance networks: an empirical study of the umbilical cord blood banking industry in emerging markets by Hsien-Tang Tsai, Shi-Zheng Huang & Chun-Hsien Wang, in Asian Journal of Technology Innovation, 2015 The concept of the cross-border collaboration network has been recognised as a useful way to obtain external R&D knowledge resources... »

Does it pay to stand on the shoulders of giants? An analysis of the inventions of star inventors in the biotechnology sector

Does it pay to stand on the shoulders of giants? An analysis of the inventions of star inventors in the biotechnology sector

  Biowebspin, January 20th, 2016 Does it pay to stand on the shoulders of giants? An analysis of the inventions of star inventors in the biotechnology sector by Jan Hohberger, in Research Policy, 2016 Previous research has highlighted the importance of star inventors for invention success and firm performance. However, we have limited knowledge regarding the indirect influence of star inventors on... »

blog-stethoscope

Factors stimulating open innovation

  Biowebspin, January 18th, 2016 Factors stimulating open innovation by Tayfun Arara and Melahat Öneren in Management Science Letters, 2016 The term innovation which is about the novelty on products, processes, services, technologies, on strategies or organizational structures is important for companies to stay in the competition and run their businesses well to gain both financial and organizatio... »

Learning from successes and failures in pharmaceutical R&D

Learning from successes and failures in pharmaceutical R&D

  Biowebspin, January 14th, 2016 Learning from successes and failures in pharmaceutical R&D by Jing-Yuan Chiou, Laura Magazzini, Fabio Pammolli, Massimo Riccaboni, in Journal of Evolutionary Economics, 2015 In this paper, we build a cumulative innovation model to understand the role of both success and failure in the learning dynamics that characterize pharmaceutical R&D. We test the predi... »

What Finance Can Learn from Biopharma Industry: A Transfer of Innovation Models

What Finance Can Learn from Biopharma Industry: A Transfer of Innovation Models

  Biowebspin, January 11th, 2016 What Finance Can Learn from Biopharma Industry: A Transfer of Innovation Models by Francesco COREA in Expert Journal of Finance, 2015 The financial sector is living a profound crisis in order to keep pace with the continuous technological breakthroughs that come out daily, while other sectors seem to be historically more growth-by-innovation-based (e.g., the pharma... »

Potential and Challenges for Start-Ups in Japan’s Biotech Industry

Potential and Challenges for Start-Ups in Japan’s Biotech Industry

  Biowebspin, January 07th, 2016 Potential and Challenges for Start-Ups in Japan’s Biotech Industry by Takao Fujiwara in Biotechnology & Biomaterials, 2015 Although Japan has both a globally rare national M&Ated healthcare program and one of the most extensive life science research capabilities in the world, there is a risk of their divergence due to Japan’s aging citizenry and the domesti... »

Road

Open innovation in early drug discovery: roadmaps and roadblocks

  Biowebspin, January 5th, 2016 Open innovation in early drug discovery: roadmaps and roadblocks by Melvin Reichman, Peter B. Simpson, in Drug Discovery Today, 2015 Open innovation in pharmaceutical R&D evolved from a triple helix of convergent paradigm shifts in academic, industrial and government research sectors. The birth of the biotechnology sector catalyzed shifts in location dynamics th... »